Peter Attia MD | New insights on GLP-1 agonists—Ozempic, Wegovy, Mounjaro, and more (AMA 64 sneak peek) @PeterAttiaMD | Uploaded October 2024 | Updated October 2024, 6 hours ago.
View show notes here: bit.ly/4exzjNe
Become a member to receive exclusive content: peterattiamd.com/subscribe
Sign up to receive Peter's email newsletter: peterattiamd.com/newsletter
In this “Ask Me Anything” (AMA) episode, Peter dives back into the increasingly popular topic of GLP-1 agonists, such as Ozempic & Mounjaro, which have garnered widespread attention for their ability to promote weight loss. Peter covers the latest findings in this rapidly evolving landscape, including new insights into their long-term efficacy, side effects, & what happens when the drug is discontinued. Peter also explores their impact on body composition & how resistance training interacts with these treatments. Additionally, he compares different GLP-1 receptor agonists & discusses promising new drugs in the pipeline. Finally, Peter addresses questions about the role of compounding pharmacies in the GLP-1 agonist market, compares oral vs. injectable options, & provides key considerations for anyone deciding whether to use a GLP-1 agonist for weight loss.
We discuss:
00:09 - The rapidly evolving landscape of GLP-1 agonists
5:14 - The mechanism of GLP-1 agonists, origin as diabetes treatments, & how they evolved into weight-loss drugs
09:08 - Overview of new data & open questions related to the benefits & risks of GLP-1 agonists
16:19 - New insights into the long-term safety of GLP-1 agonists & side effects
In the full episode, we also discuss:
The long-term efficacy of GLP-1 agonists, financial barriers, & more;
The mechanisms behind GLP-1 agonists' ability to promote weight loss;
New data on body weight changes after discontinuing the drug;
Effects of GLP-1 agonists on lean mass & body composition, & the role of protein & resistance training in preserving muscle;
Semaglutide vs. tirzepatide;
How compounding pharmacies affect availability of GLP-1 drugs & the available formulations;
How oral formulations of GLP-1 drugs compare to injectable formulations;
How sublingual (under tongue) formulations of GLP-1 drugs compare to injectable formulations;
Guidance for using compounding pharmacies to purchase GLP-1 agonists;
Data on retatrutide—a promising new triple receptor agonist in the pipeline;
Can GLP-1 agonists be beneficial for sleep apnea & immune function?;
Potential neuroprotective benefits of GLP-1 agonists: impact on dementia risk;
Exploring why GLP-1 agonists may reduce the risk of cancer, kidney disease, & cardiovascular disease;
How GLP-1 agonists might boost fertility in women;
Early indications that GLP-1 agonists may help treat substance abuse disorders;
Potential health risks of GLP-1 agonists: addressing thyroid cancer concerns & the unknowns due to lack of data;
Examining the potential link between GLP-1 agonists & increased depression or suicidal ideation;
Major remaining questions: the effects of cyclic use, rebound appetite, impact on adolescents' development, & more;
Key considerations when deciding whether to use a GLP-1 agonist for weight loss;
--------
About:
The Peter Attia Drive is a deep-dive podcast focusing on maximizing longevity, & all that goes into that from physical to cognitive to emotional health. With over 90 million episodes downloaded, it features topics including exercise, nutritional biochemistry, cardiovascular disease, Alzheimer’s disease, cancer, mental health, & much more.
Peter Attia is the founder of Early Medical, a medical practice that applies the principles of Medicine 3.0 to patients with the goal of lengthening their lifespan & simultaneously improving their healthspan.
Learn more: peterattiamd.com
Connect with Peter on:
Facebook: bit.ly/PeterAttiaMDFB
Twitter: bit.ly/PeterAttiaMDTW
Instagram: bit.ly/PeterAttiaMDIG
Subscribe to The Drive:
Apple Podcast: bit.ly/TheDriveApplePodcasts
Overcast: bit.ly/TheDriveOvercast
Spotify: bit.ly/TheDriveSpotify
Google Podcasts: bit.ly/TheDriveGoogle
Disclaimer: This podcast is for general informational purposes only & does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information & the materials linked to this podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they have, & they should seek the assistance of their healthcare professionals for any such conditions. I take conflicts of interest very seriously. For all of my disclosures & the companies I invest in or advise, please visit my website where I keep an up-to-date & active list of such companies. For a full list of our registered & unregistered trademarks, trade names, & service marks, please review our Terms of Use: peterattiamd.com/terms-of-use
View show notes here: bit.ly/4exzjNe
Become a member to receive exclusive content: peterattiamd.com/subscribe
Sign up to receive Peter's email newsletter: peterattiamd.com/newsletter
In this “Ask Me Anything” (AMA) episode, Peter dives back into the increasingly popular topic of GLP-1 agonists, such as Ozempic & Mounjaro, which have garnered widespread attention for their ability to promote weight loss. Peter covers the latest findings in this rapidly evolving landscape, including new insights into their long-term efficacy, side effects, & what happens when the drug is discontinued. Peter also explores their impact on body composition & how resistance training interacts with these treatments. Additionally, he compares different GLP-1 receptor agonists & discusses promising new drugs in the pipeline. Finally, Peter addresses questions about the role of compounding pharmacies in the GLP-1 agonist market, compares oral vs. injectable options, & provides key considerations for anyone deciding whether to use a GLP-1 agonist for weight loss.
We discuss:
00:09 - The rapidly evolving landscape of GLP-1 agonists
5:14 - The mechanism of GLP-1 agonists, origin as diabetes treatments, & how they evolved into weight-loss drugs
09:08 - Overview of new data & open questions related to the benefits & risks of GLP-1 agonists
16:19 - New insights into the long-term safety of GLP-1 agonists & side effects
In the full episode, we also discuss:
The long-term efficacy of GLP-1 agonists, financial barriers, & more;
The mechanisms behind GLP-1 agonists' ability to promote weight loss;
New data on body weight changes after discontinuing the drug;
Effects of GLP-1 agonists on lean mass & body composition, & the role of protein & resistance training in preserving muscle;
Semaglutide vs. tirzepatide;
How compounding pharmacies affect availability of GLP-1 drugs & the available formulations;
How oral formulations of GLP-1 drugs compare to injectable formulations;
How sublingual (under tongue) formulations of GLP-1 drugs compare to injectable formulations;
Guidance for using compounding pharmacies to purchase GLP-1 agonists;
Data on retatrutide—a promising new triple receptor agonist in the pipeline;
Can GLP-1 agonists be beneficial for sleep apnea & immune function?;
Potential neuroprotective benefits of GLP-1 agonists: impact on dementia risk;
Exploring why GLP-1 agonists may reduce the risk of cancer, kidney disease, & cardiovascular disease;
How GLP-1 agonists might boost fertility in women;
Early indications that GLP-1 agonists may help treat substance abuse disorders;
Potential health risks of GLP-1 agonists: addressing thyroid cancer concerns & the unknowns due to lack of data;
Examining the potential link between GLP-1 agonists & increased depression or suicidal ideation;
Major remaining questions: the effects of cyclic use, rebound appetite, impact on adolescents' development, & more;
Key considerations when deciding whether to use a GLP-1 agonist for weight loss;
--------
About:
The Peter Attia Drive is a deep-dive podcast focusing on maximizing longevity, & all that goes into that from physical to cognitive to emotional health. With over 90 million episodes downloaded, it features topics including exercise, nutritional biochemistry, cardiovascular disease, Alzheimer’s disease, cancer, mental health, & much more.
Peter Attia is the founder of Early Medical, a medical practice that applies the principles of Medicine 3.0 to patients with the goal of lengthening their lifespan & simultaneously improving their healthspan.
Learn more: peterattiamd.com
Connect with Peter on:
Facebook: bit.ly/PeterAttiaMDFB
Twitter: bit.ly/PeterAttiaMDTW
Instagram: bit.ly/PeterAttiaMDIG
Subscribe to The Drive:
Apple Podcast: bit.ly/TheDriveApplePodcasts
Overcast: bit.ly/TheDriveOvercast
Spotify: bit.ly/TheDriveSpotify
Google Podcasts: bit.ly/TheDriveGoogle
Disclaimer: This podcast is for general informational purposes only & does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information & the materials linked to this podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they have, & they should seek the assistance of their healthcare professionals for any such conditions. I take conflicts of interest very seriously. For all of my disclosures & the companies I invest in or advise, please visit my website where I keep an up-to-date & active list of such companies. For a full list of our registered & unregistered trademarks, trade names, & service marks, please review our Terms of Use: peterattiamd.com/terms-of-use
